Vudalimab or Pembrolizumab with Chemotherapy for Lung Cancer

Phase 1 & 2

Recruiting

Research Sponsored by Xencor, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Histologically confirmed, locally advanced (unresectable) or metastatic nonsquamous NSCLC

ECOG performance status score of 0 or 1

Timeline

Screening 3 weeks

Treatment Varies

Follow Up day 1 to 2.5 years

Awards & highlights

No Placebo-Only Group

Summary

This trial aims to find the right amount of vudalimab to use alongside chemotherapy for patients with a specific type of lung cancer. The study will also compare the effectiveness and safety of vud

Who is the study for?

This trial is for adults with advanced non-squamous NSCLC who haven't had treatment before. They should not have certain gene mutations or a high PD-L1 level, and must be in good physical condition with a life expectancy of at least 3 months. Their liver, kidney, thyroid, and bone marrow must function well.

What is being tested?

The study tests Vudalimab combined with chemotherapy (Carboplatin + Pemetrexed) against Pembrolizumab with the same chemo as first-line treatments. Part 1 determines the best dose of Vudalimab; Part 2 compares its effectiveness and safety to Pembrolizumab.

What are the potential side effects?

Possible side effects include immune-related reactions affecting organs, infusion-related symptoms, fatigue, nausea from chemotherapy drugs used alongside both Vudalimab and Pembrolizumab.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My lung cancer is advanced, cannot be surgically removed, and is not squamous type.

Select...

I am fully active or can carry out light work.

Select...

My cancer does not have certain genetic changes that can be treated with specific drugs.

Select...

I haven't received any systemic treatment for advanced lung cancer.

Select...

I'm sorry, but the term "Key" on its own is not clear enough for me to provide a simplified summary. If you could provide more context or clarify the term, I'd be happy to help!